Clinical trial
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients…
NCT00044135 · Triangle Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00044135 |
|---|---|
| Title | A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus. |
| Official title | A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus. |
| Lead sponsor | Triangle Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | clevudine (drug) |
| Enrollment | 30 |
| Start date | Aug 1, 2002 |
| First posted | Aug 21, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, China, France, Singapore, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: